Kane Biotech Inc. (CVE:KNE – Get Free Report)’s stock price reached a new 52-week low on Monday . The company traded as low as C$0.03 and last traded at C$0.04, with a volume of 71191 shares. The stock had previously closed at C$0.03.
Kane Biotech Price Performance
The company has a fifty day moving average of C$0.03 and a 200-day moving average of C$0.04. The company has a current ratio of 0.45, a quick ratio of 0.39 and a debt-to-equity ratio of -135.17. The stock has a market cap of C$6.15 million, a PE ratio of -1.50 and a beta of 0.97.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Recommended Stories
- Five stocks we like better than Kane Biotech
- FuelCell Energy Just Got a Wake-Up Call From Wall Street
- Short Sellers Are Piling Into Wingstop, But Analysts See Big Upside
- Synchrony’s Comeback Is Hiding in Plain Sight
- Uranium Energy Corp Melts Down—Nuclear Opportunity at Hand
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
